Literature DB >> 10649205

In vivo adenovirus-mediated endothelial nitric oxide synthase gene transfer ameliorates lung allograft ischemia-reperfusion injury.

T Suda1, B N Mora, F D'Ovidio, J A Cooper, M Hiratsuka, W Zhang, T Mohanakumar, G A Patterson.   

Abstract

OBJECTIVE: Nitric oxide regulates vascular tone, inhibits platelet aggregation, and inhibits leukocyte adhesion, all of which are important modulators of ischemia-reperfusion injury. This study aimed to determine the effects of endothelial constitutive nitric oxide synthase gene transfer on ischemia-reperfusion injury in a rat lung transplant model.
METHODS: In group I, donor animals were injected intravenously with 5 x 10(9) pfu of adenovirus-encoding endothelial constitutive nitric oxide synthase. Groups II and III served as controls, whereby donor animals were injected with either 5 x 10(9) pfu of adenovirus encoding beta-galactosidase or saline solution, respectively. Twenty-four hours after injection, left lungs were harvested and preserved for 18 hours at 4 degrees C, then implanted into isogeneic recipients, which were put to death 24 hours later. Recombinant endothelial constitutive nitric oxide synthase gene expression was evaluated by Western blotting and immunohistochemistry. Lung grafts were assessed by measuring arterial oxygenation, myeloperoxidase activity, and wet/dry weight ratios.
RESULTS: Western blotting confirmed the overexpression of endothelial constitutive nitric oxide synthase in lungs so transfected compared with controls. Twenty-four hours after reperfusion, mean arterial oxygenation was significantly improved in group I compared with group II and III controls (189.4 +/- 47.1 mm Hg vs 71.7 +/- 8.9 mm Hg and 67.8 +/- 12.2 mm Hg, P =.02, P =.01, respectively). Myeloperoxidase activity, a reflection of tissue neutrophil sequestration, was also significantly reduced in group I compared with groups II and III (0.136 +/- 0.038 DeltaOD/mg/min vs 0. 587 +/- 0.077 and 0.489 +/- 0.126 DeltaOD/mg/min, P =.001, P =.01, respectively).
CONCLUSION: Adenovirus-mediated gene transfer with endothelial constitutive nitric oxide synthase ameliorates ischemia-reperfusion injury as manifested by significantly improved oxygenation and decreased neutrophil sequestration in transplanted lung isografts. Endothelial constitutive nitric oxide synthase gene transfer may reduce acute lung dysfunction after lung transplantation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10649205     DOI: 10.1016/S0022-5223(00)70185-1

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

Review 1.  Lung transplantation: opportunities for research and clinical advancement.

Authors:  David S Wilkes; Thomas M Egan; Herbert Y Reynolds
Journal:  Am J Respir Crit Care Med       Date:  2005-07-14       Impact factor: 21.405

2.  CD47 blockade reduces ischemia-reperfusion injury and improves outcomes in a rat kidney transplant model.

Authors:  Yiing Lin; Pamela T Manning; Jianluo Jia; Joseph P Gaut; Zhenyu Xiao; Benjamin J Capoccia; Chun-Cheng Chen; Ronald R Hiebsch; Gundumi Upadhya; Thalachallour Mohanakumar; William A Frazier; William C Chapman
Journal:  Transplantation       Date:  2014-08-27       Impact factor: 4.939

3.  Ex vivo adenoviral vector gene delivery results in decreased vector-associated inflammation pre- and post-lung transplantation in the pig.

Authors:  Jonathan C Yeung; Dirk Wagnetz; Marcelo Cypel; Matthew Rubacha; Terumoto Koike; Yi-Min Chun; Jim Hu; Thomas K Waddell; David M Hwang; Mingyao Liu; Shaf Keshavjee
Journal:  Mol Ther       Date:  2012-03-27       Impact factor: 11.454

Review 4.  Gene Therapy: Will the Promise of Optimizing Lung Allografts Become Reality?

Authors:  Qimeng Gao; Isabel F DeLaura; Imran J Anwar; Samuel J Kesseli; Riley Kahan; Nader Abraham; Aravind Asokan; Andrew S Barbas; Matthew G Hartwig
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

5.  A physiologic and biochemical profile of clinically rejected lungs on a normothermic ex vivo lung perfusion platform.

Authors:  Timothy J George; George J Arnaoutakis; Claude A Beaty; Simran K Jandu; Lakshmi Santhanam; Dan E Berkowitz; Ashish S Shah
Journal:  J Surg Res       Date:  2012-11-27       Impact factor: 2.192

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.